Long Term Bio
Long only, biotech, healthcare, short only

Idera Pharmaceuticals: Set To Ride A 200% Gain In 2014

There has been one small-cap biotechnology company riding under the radar of many investors. This company is known as Idera Pharmaceuticals (NASDAQ:IDRA), that is developing treatments for autoimmune diseases and certain genetically defined forms of B-Cell lymphoma. The current share price for Idera is around $3.71 per share with a market cap of $256 Million. We believe that with the current pipeline the company should trade at around $10 per share which would give it a market cap around $650 million. This falls more in line with other biotechnology companies that have compounds in phase 2 clinical trials. Investors should consider the prospects, and take notice of big institutional buyers that have bought some shares of the stock...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details